Advertisement

Calcium Entry Blockers in Migraine: The State of the Art

  • E. L. H. Spierings
Conference paper

Abstract

The calcium entry blockers or calcium antagonists are a group of medications that share the potential of inhibiting the movement of calcium into cells and cell organelles. They do so through a number of different mechanisms, such as, for instance, the blockade of potential- or receptor-operated calcium channels or the blockade of calcium influx under conditions of overload. Chemically the calcium entry blockers represent medications of different groups with little or no relationship to each other and little or no predictability with regard to activity and/or mechanism [24].

Keywords

Cerebral Blood Flow Cluster Head Cluster Headache Migraine Attack Spreading Depression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Amery WK, Wauquier A, Van Neuten JM, DeClerck F, Van Treempts JV, Janssen PAJ (1981) The anti-migrainous pharmacology of flunarizine (R14950), a calcium antagonist. Drugs Exp Clin Res 7:1–10Google Scholar
  2. 2.
    Andersen AR, Friberg L, Olsen TS, Olesen J (1988) Delayed hyperemia following hypoperfusion in classic migraine. Arch Neurol 45:154–159PubMedCrossRefGoogle Scholar
  3. 3.
    Boiardi A, Gemma M, Porta E, Peccarisi C, Bussone G (1986) Calcium entry blocker: treatment in acute pain in cluster headache patients. Ital J Neurol Sci 7:531–534PubMedCrossRefGoogle Scholar
  4. 4.
    Gardner-Medwin AR (1981) The effect of carbon dioxide and oxygen on Leão’s spreading depression: evidence supporting a relationship to migraine. J Physiol 316:23P–24PGoogle Scholar
  5. 5.
    Gelmers HJ (1982) Common migraine attacks preceded by focal hyperemia and parietal oligemia in rCBF pattern. Cephalalgia 2:29–32PubMedCrossRefGoogle Scholar
  6. 6.
    Hardebo JE (1984) The involvement of trigeminal substance P neurons in cluster headache. A hypothesis. Headache 24:294–304PubMedCrossRefGoogle Scholar
  7. 7.
    Kahan A, Weber S, Amor B, Guerin F, DeGeorges M (1983) Nifedipine in the treatment of migraine in patients with Raynaud’s phenomenon. N Engl J Med 308:1102–1103PubMedGoogle Scholar
  8. 8.
    Lauritzen M, Jorgenesen MB, Diemer NH, Gjedde A, Hansen AJ (1982) Persistent oligemia of rat cerebral cortex in the wake of spreading depression. Ann Neurol 12:469–474PubMedCrossRefGoogle Scholar
  9. 9.
    Lauritzen M, Olsen TS, Lassen NA, Paulson OB (1983) Changes in regional cerebral blood flow during the course of classic migraine attacks. Ann Neurol 633–641Google Scholar
  10. 10.
    Louis P (1981) A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine. Headache 21:235–239PubMedCrossRefGoogle Scholar
  11. 11.
    Mathew NT, Hrastnik F, Meyer JS (1976) Regional cerebral blood flow in the diagnosis of vascular headache. Headache 15:252–260PubMedCrossRefGoogle Scholar
  12. 12.
    Meyer JS, Hardenberg J (1983) Clinical effectiveness of calcium entry blockers in prophylactic treatment of migraine and cluster headache. Headache 23:266–277PubMedCrossRefGoogle Scholar
  13. 13.
    O’Brien MD (1971) Cerebral blood flow changes in migraine. Headache 10:139–143PubMedCrossRefGoogle Scholar
  14. 14.
    Olesen J, Larsen B, Lauritzen M (1981) Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 9:344–352PubMedCrossRefGoogle Scholar
  15. 15.
    Olesen J, Tfelt-Hansen P, Henriksen L, Larsen B (1981) The common migraine attack may not be initiated by cerebral ischemia. Lancet 11:438–440CrossRefGoogle Scholar
  16. 16.
    Olsen TS, Friberg L, Lassen NA (1987) Ischemia may be the primary cause of the neurologic déficits in classic migraine. Arch Neurol 44:156–161CrossRefGoogle Scholar
  17. 17.
    Olsen TS, Friberg L, Ronager J (1987) Cerebrovascular reactivity is completely abolished during attacks of classic migraine. Cephalalgia 7 (Suppl 6): 103–105Google Scholar
  18. 18.
    Spierings ELH (1987) Cluster headache: distinguishing features. Drug Therapy 17(5): 56–67Google Scholar
  19. 19.
    Spierings ELH (1987) Cluster headache: relieving and preventing attacks. Drug Therapy 17(5):68–72Google Scholar
  20. 20.
    Spierings ELH (1987) Migraine headaches: mechanisms and management. New Dev Med 2:59–76Google Scholar
  21. 21.
    Spierings ELH (1988) Clinical and experimental evidence for a role of calcium entry blockers in the treatment of migraine. Ann NY Acad Sci 522:676–689PubMedCrossRefGoogle Scholar
  22. 22.
    Spierings ELH, Gabai IJ (1989) Prophylactic treatment of cluster headache with verapamil. Headache 29:167–168PubMedCrossRefGoogle Scholar
  23. 23.
    Spierings ELH, Messinger HB (1988) Flunarizine versus pizotifen in migraine prophylaxis: a review of comparative studies. Cephalalgia (in press)Google Scholar
  24. 24.
    Vanhoutte PM (1987) The expert committee of the World Health Organization on classification of calcium antagonists: the viewpoint of the raporteur. Am J Cardiol 58:3A–8ACrossRefGoogle Scholar
  25. 25.
    Wauquier A, Ashton D, Marranes R (1985) The effects of flunarizine in experimental models related to the pathogenesis of migraine. Cephalalgia 5 (Suppl 2): 119–120PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • E. L. H. Spierings
    • 1
    • 2
  1. 1.The Headache Research Foundation and John R. Graham Headache CentreThe Faulkner HospitalUSA
  2. 2.Department of NeurologyTufts University School of MedicineBostonUSA

Personalised recommendations